An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the most common malignancy and the leading cause of cancer death worldwide. In this report, we describe a patient with NSCLC who was treated with continuation of Bevacizumab (Bev) beyond progression to first-line Bev-based chemotherapy. The prolonged treatment w...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Biol Ther
Main Authors: Roviello, Giandomenico, Francini, Edoardo, Perrella, Armando, Laera, Letizia, Mazzei, Maria Antonietta, Guerrini, Susanna, Petrioli, Roberto
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2015
Subjects:
Bedside to Bench Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847824/
https://ncbi.nlm.nih.gov/pubmed/26418066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095410
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items